NCT00047671

Ethnic Variations in Antidepressant Response

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: National Institute of Mental Health (NIMH) · NIH
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].

Detailed description

Depressed patients vary substantially in their responses to antidepressants. Genetic factors may account for a large part of these differences in response. This study will include both African Americans and Caucasians to examine the role of genetic factors in treatment response. Participants receive citalopram (Celexa) for 8 weeks and a placebo for 1 week. Visits occur once a week for 11 weeks. A variety of interviews, scales, tests, and questionnaires are used to assess participants.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	Citalopram	PDA Approved antidepressant

Timeline

• Start date: 2002-06-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2002-10-16
• Last updated: 2009-08-04

Locations

3 sites across 1 country: United States